AstraZeneca Divests Rights of Migraine Drug to Grünenthal
Germany-based Grünenthal will gain rights to market and sell Zomig (zolmitriptan) outside of Japan.
AstraZeneca has entered into an agreement with Grünenthal for the global rights of its migraine drug Zomig (zolmitriptan) outside Japan. Grünenthal will acquire the rights to Zomig in all markets outside Japan, including the United States, where the rights were previously licensed to Impax Pharmaceuticals (Impax). Impax will continue to market Zomig in the US.
Grünenthal will pay AstraZeneca $200 million upon completion of the deal. AstraZeneca will also receive up to an additional $102 million in future milestone payments. During the transition period, AstraZeneca will continue to manufacture and supply the medicine to Grünenthal. The transaction is expected to complete in the second quarter of 2017, subject to customary closing conditions and regulatory clearances.
Revenues from Zomig outside Japan were $96 million in 2016, including product sales and externalization revenue.
Source: AstraZeneca
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.
